Pacira BioSciences, Inc.

For the period ended Mar 31, 2026. Filed Apr 30, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 30, 2026

PCRX$36.46+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	March 31,2026	December 31,2025
ASSETS
Current assets:
Cash and cash equivalents	$144,306	$158,545
Short-term available-for-sale investments	57,874	79,879
Accounts receivable, net	125,635	124,069
Inventories, net	150,370	152,863
Prepaid expenses and other current assets	36,776	32,618
Total current assets	514,961	547,974
Fixed assets, net	136,281	140,690
Right-of-use assets, net	39,409	41,777
Goodwill	19,773	20,214
Intangible assets, net	353,227	368,100
Deferred tax assets	122,115	123,854
Investments and other assets	22,768	22,308
Total assets	$1,208,534	$1,264,917
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$14,012	$15,150
Accrued expenses	84,957	95,601
Lease liabilities	9,818	9,839
Total current liabilities	108,787	120,590
Long-term debt, net	367,656	372,189
Lease liabilities	33,705	36,176
Contingent consideration	15,789	18,066
Deferred tax liabilities	4,093	4,213
Other liabilities	24,611	20,572
Total liabilities	554,641	571,806
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025	—	—
Common stock, par value $0.001; 250,000,000 shares authorized; 48,328,201 shares issued and 39,309,610 shares outstanding at March 31, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December 31, 2025	48	48
Treasury stock, at cost, inclusive of excise tax and broker fees, 9,018,591 and 6,774,038 shares at March 31, 2026 and December 31, 2025, respectively	(227,013)	(176,565)
Additional paid-in capital	1,073,809	1,064,623
Accumulated deficit	(196,406)	(199,322)
Accumulated other comprehensive income	3,455	4,327
Total stockholders’ equity	653,893	693,111
Total liabilities and stockholders’ equity	$1,208,534	$1,264,917

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.